PT-141
Also known as: Bremelanotide, Vyleesi
Buy in shop
PT-141 from $74/kit
3 verified vendors, ≥99% purity, COAs included.
Key Facts: PT-141
- Category
- Sexual Health
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - HSDD in premenopausal women
- Administration
- Subcutaneous injection (autoinjector available)
- Typical Dose
- 1.75 mg as needed
- Frequency
- As needed, at least 45 min before activity
- Duration
- As needed, at least 45 min before activity
Mechanism of Action
PT-141 activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways, affecting desire and arousal centrally.
Research Summary
FDA approved June 2019 for women with HSDD based on trials with 1,247 subjects. 2024 male observational study (21 men) showed efficacy for ED and sexual dysfunction, particularly in those who failed PDE5 inhibitors. Phase II male trials ongoing with Phase III planned for 2025. Works through central nervous system pathways rather than peripheral vascular mechanisms.
Dosing Information
Typical Dosingⓘ
Community experience
1.75 mg as needed
0.5-2 mg per dose
As needed, at least 45 min before activity
FDA-approved dose is 1.75 mg. Not for daily use - max 8 doses per month. Can cause nausea and flushing.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
1.75 mg (FDA approved for women)
Research doses for men varied
Duration
As needed, at least 45 min before activity
Administration
Subcutaneous injection (autoinjector available)
Timing & Administration
Best Time to Take
1-2 hours before sexual activity
As needed, max once per 24 hours
Food Recommendation
With or without food
Why This Timing?
PT-141 (Bremelanotide) takes 45-60 minutes to work. Timing before anticipated activity is optimal.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (40% - most common)
- ●Facial flushing (20%)
- ●Injection site reactions
- ●Headache
- ●Transient blood pressure increase
- ●Skin hyperpigmentation with frequent use
- ●Vomiting
- ●Fatigue
- ●FDA approved (Vyleesi) for HSDD in women
References
- https://pubmed.ncbi.nlm.nih.gov/31599840/
- https://pubmed.ncbi.nlm.nih.gov/16839319/
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Research This Peptide Further
Buy in shop
PT-141 from $74/kit
3 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does PT-141 do?
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Derived from Melanotan II research.
How does PT-141 work?
PT-141 activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways, affecting desire and arousal centrally.
Is PT-141 FDA approved?
Yes, PT-141 is FDA approved. FDA Approved - HSDD in premenopausal women
What are the side effects of PT-141?
Reported side effects include: Nausea (40% - most common), Facial flushing (20%), Injection site reactions, Headache, Transient blood pressure increase. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of PT-141?
Community-reported common dose: 1.75 mg as needed (As needed, at least 45 min before activity). Range: 0.5-2 mg per dose. Administration: Subcutaneous injection (autoinjector available). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with PT-141 or used in similar applications.
Melanotan II
ResearchA synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Known for inducing skin tanning and having effects on libido and sexual function.
Sexual HealthSemaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossOxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
Growth HormoneSelank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveWant updates on PT-141 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.